GlaxoSmithKline PLC — Regulatory Filings 2012

Jan 10, 2012

FORM 6-K/A

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending January 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £14.70 per Ordinary share and $45.53 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2011 to 30 December 2011:

Non Executive Director	Ordinary Shares
Sir Christopher Gent	2,295.918
Prof. Sir Roy Anderson	573.980
Dr Stephanie Burns	325.294
Ms Stacey Cartwright	318.878
Mr Lawrence Culp	650.588
Sir Crispin Davis	2,125.850
Ms Judy Lewent	162.647*
Sir Deryck Maughan	650.588
Mr James Murdoch	1,275.510
Dr Daniel Podolsky	683.117
Mr Tom de Swaan	786.565
Sir Robert Wilson	573.980

The Company and the Non-Executive Directors were informed of these allocations on

3 January 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

10 January 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: January 10, 2012

By: VICTORIA WHYTE

---

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc